Given the fact that there are no drugs currently available to inhibit ATAD3A, our study draws attention to extending the development of anti-HNSCC therapies to include novel anti-ATAD3A strategies. The gene discussed is ATAD3A; the disease is head and neck squamous cell carcinoma.